Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

A collaborative Phase III study by Merck, Seagen and Astellas to treat locally advanced and metastatic urothelial cancer hit its dual primary endpoints, the companies announced Friday.